Pardes Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Pardes Biosciences generated cash of -$71,976,000, which is less than the previous year. Cash used in financing activities reached the amount of -$397,000 last year. Net change in cash is therefore -$209,394,000.
Cash Flow
| 2021 | -36.91M | 0 | 302.18M |
|---|---|---|---|
| 2022 | -71.97M | -137.02M | -397K |
PRDS Cash Flow Statement (2021 – 2022)
| 2022 | 2021 | |
|---|---|---|
Cash at beginning of period | 268.67M | 3.41M |
Operating activities | ||
Net income | -96.63M | -38.51M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | -1 | 0 |
Stock-based compensation expense | 10.56M | 1.22M |
| Deferred income tax benefit | 10.56M | 1.22M |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 0 | 0 |
Inventories | 0 | 0 |
Accounts payable | 2.77M | 756K |
Cash generated by operating activities | -71.97M | -36.91M |
Investing activities | ||
Purchases Of Investments | -138.20M | 0 |
Investments In Property Plant And Equipment | 0 | 0 |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | -137.02M | 0 |
Financing activities | ||
Common Stock Issued | 0 | 243.43M |
Payments for dividends | 0 | 0 |
Repurchases of common stock | 0 | 0 |
Repayments of term debt | 0 | -10M |
Cash used in financing activities | -397K | 302.18M |
Net Change In Cash | -209.39M | 265.26M |
Cash at end of period | 59.28M | 268.67M |
| Data source | Data source |